EDSA Quote, Financials, Valuation and Earnings

ESSA Pharma has a net margin of -- compared to Edesa Biotech's net margin of --. Edesa Biotech's return on equity of -- beat ESSA Pharma's return on equity of --.

Edesa Biotech has a consensus price target of $19.00, signalling upside risk potential of 829.1%. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -2.25%. Given that Edesa Biotech has higher upside potential than ESSA Pharma, analysts believe Edesa Biotech is more attractive than ESSA Pharma.

Edesa Biotech has a beta of 0.547, which suggesting that the stock is 45.291% less volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.686, suggesting its more volatile than the S&P 500 by 68.618%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than ESSA Pharma quarterly revenues of --. Edesa Biotech's net income of -$1.6M is higher than ESSA Pharma's net income of -$8.5M. Notably, Edesa Biotech's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 20.23x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -- compared to Edesa Biotech's net margin of -1559.32%. Edesa Biotech's return on equity of -- beat Lexaria Bioscience's return on equity of -118.15%.

Edesa Biotech has a consensus price target of $19.00, signalling upside risk potential of 829.1%. On the other hand Lexaria Bioscience has an analysts' consensus of $7.00 which suggests that it could grow by 548.15%. Given that Edesa Biotech has higher upside potential than Lexaria Bioscience, analysts believe Edesa Biotech is more attractive than Lexaria Bioscience.

Edesa Biotech has a beta of 0.547, which suggesting that the stock is 45.291% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.806%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than Lexaria Bioscience quarterly revenues of $174K. Edesa Biotech's net income of -$1.6M is higher than Lexaria Bioscience's net income of -$2.7M. Notably, Edesa Biotech's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 20.23x versus 32.73x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

ProMIS Neurosciences has a net margin of -- compared to Edesa Biotech's net margin of --. Edesa Biotech's return on equity of -- beat ProMIS Neurosciences's return on equity of --.

Edesa Biotech has a consensus price target of $19.00, signalling upside risk potential of 829.1%. On the other hand ProMIS Neurosciences has an analysts' consensus of $8.00 which suggests that it could grow by 1493.59%. Given that ProMIS Neurosciences has higher upside potential than Edesa Biotech, analysts believe ProMIS Neurosciences is more attractive than Edesa Biotech.

Edesa Biotech has a beta of 0.547, which suggesting that the stock is 45.291% less volatile than S&P 500. In comparison ProMIS Neurosciences has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.367%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. ProMIS Neurosciences pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than ProMIS Neurosciences quarterly revenues of --. Edesa Biotech's net income of -$1.6M is lower than ProMIS Neurosciences's net income of $9.3M. Notably, Edesa Biotech's price-to-earnings ratio is -- while ProMIS Neurosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 20.23x versus -- for ProMIS Neurosciences. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -- compared to Edesa Biotech's net margin of --. Edesa Biotech's return on equity of -- beat Xenon Pharmaceuticals's return on equity of --.

Edesa Biotech has a consensus price target of $19.00, signalling upside risk potential of 829.1%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.18 which suggests that it could grow by 63.27%. Given that Edesa Biotech has higher upside potential than Xenon Pharmaceuticals, analysts believe Edesa Biotech is more attractive than Xenon Pharmaceuticals.

Edesa Biotech has a beta of 0.547, which suggesting that the stock is 45.291% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.174%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than Xenon Pharmaceuticals quarterly revenues of --. Edesa Biotech's net income of -$1.6M is higher than Xenon Pharmaceuticals's net income of -$65.7M. Notably, Edesa Biotech's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 20.23x versus 207.11x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.